Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia ; volume:13 ; number:1 ; day:19 ; month:11 ; year:2020 ; pages:1-13 ; date:12.2020
Journal of hematology & oncology ; 13, Heft 1 (19.11.2020), 1-13, 12.2020
- Urheber
-
Gebru, Melat T.
Wang, Hong-Gang
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-020-00992-1
- URN
-
urn:nbn:de:101:1-2020123019353219422824
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gebru, Melat T.
- Wang, Hong-Gang
- SpringerLink (Online service)
Ähnliche Objekte (12)
FLT3 inhibitors in acute myeloid leukemia
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
FLT3 inhibitors in acute myeloid leukemia
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
FLT3 inhibitors in acute myeloid leukemia
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
RSK1 dependency in FLT3-ITD acute myeloid leukemia
Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia